<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35562734</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1479-5876</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of translational medicine</Title>
          <ISOAbbreviation>J Transl Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.</ArticleTitle>
        <Pagination>
          <StartPage>212</StartPage>
          <MedlinePgn>212</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">212</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-022-03416-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Hepatocellular carcinoma (HCC) is the most common pathological type of liver cancer. Valosin-containing protein (VCP) is a member of the AAA-ATPase family associated with multiple molecular functions and involved in tumor metastasis and prognosis. However, the role of VCP in HCC progression is still unclear.</AbstractText>
          <AbstractText Label="METHODS">We examined the expression of VCP in HCC using the RNA sequencing and microarray data from public databases and measured it in clinical samples and cell lines by western blot, and immunohistochemistry (IHC). We also evaluated the correlation between VCP and clinical features. The VCP-interacting proteins were identified by co-immunoprecipitation combined with mass spectrometry (CoIP/MS). The underlying molecular mechanisms were investigated using in vitro and in vivo models of HCC.</AbstractText>
          <AbstractText Label="RESULTS">We found that VCP expression is significantly increased in tumor tissues and is associated with advanced TNM stages and poorer prognosis in HCC patients. In vitro analyses revealed that VCP overexpression promoted HCC cell proliferation, migration, and invasion via PI3K/AKT/mTOR pathway activation. Conversely, VCP knockdown resulted in the reverse phenotypes. In vivo studies indicated that up-regulated VCP expression accelerated tumor growth in a subcutaneous HCC model. The D1 domain of VCP and A box of HMGB1 were identified as the critical regions for their interaction, and D1 area was required for the tumor-promoting effects induced by VCP expression. VCP enhanced the protein stability of HMGB1 by decreasing its degradation via ubiquitin-proteasome process. Inhibition of HMGB1 markedly attenuated VCP-mediated HCC progression and downstream activation of PI3K/AKT/mTOR signals.</AbstractText>
          <AbstractText Label="CONCLUSION">Collectively, these findings demonstrate that VCP is a potential prognostic biomarker in HCC and exhibits oncogenic roles via PI3K/AKT/mTOR pathway activation. HMGB1 played an essential role in VCP-mediated HCC progression, indicating that VCP and HMGB1 are potential therapeutic targets in human HCC.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pu</LastName>
            <ForeName>Zhangya</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-5721-3512</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duda</LastName>
            <ForeName>Dan G</ForeName>
            <Initials>DG</Initials>
            <AffiliationInfo>
              <Affiliation>E.L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox-734, Boston, 02114, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yuanyuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Cancer Proteomics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pei</LastName>
            <ForeName>Siya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaofang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>Panpan</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Zebing</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China. pengfang@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Cancer Proteomics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, Hunan, China. pengfang@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Xingwang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China. lebithu@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Xuegong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China. xgfan@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA260857</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Transl Med</MedlineTA>
        <NlmUniqueID>101190741</NlmUniqueID>
        <ISSNLinking>1479-5876</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C585491">HMGB1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.4.6</RegistryNumber>
          <NameOfSubstance UI="C000614178">VCP protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.4.6</RegistryNumber>
          <NameOfSubstance UI="D000074405">Valosin Containing Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024243" MajorTopicYN="Y">HMGB1 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074405" MajorTopicYN="N">Valosin Containing Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">HMGB1</Keyword>
        <Keyword MajorTopicYN="Y">Hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="Y">PI3K/AKT/mTOR pathway</Keyword>
        <Keyword MajorTopicYN="Y">Tumor progression</Keyword>
        <Keyword MajorTopicYN="Y">VCP</Keyword>
      </KeywordList>
      <CoiStatement>Dr. Duda received consultant fees from Bayer, BMS, Simcere, Sophia Biosciences, and Surface Oncology and has received research grants from Bayer, Merrimack, Exelixis, and BMS. No reagents or support from these companies were used for this study. All the other authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>23</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35562734</ArticleId>
        <ArticleId IdType="pmc">PMC9102726</ArticleId>
        <ArticleId IdType="doi">10.1186/s12967-022-03416-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s12967-022-03416-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018;391(10127):1301–1314. doi: 10.1016/S0140-6736(18)30010-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)30010-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang YF, Zhang MF, Tian QH, Fu J, Yang X, Zhang CZ, et al.  SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma. Mol Cancer. 2018;17(1):117. doi: 10.1186/s12943-018-0872-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-018-0872-3</ArticleId>
            <ArticleId IdType="pmc">PMC6081940</ArticleId>
            <ArticleId IdType="pubmed">30089483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21492</ArticleId>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al.  Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi: 10.1038/nrdp.2016.18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2016.18</ArticleId>
            <ArticleId IdType="pubmed">27158749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu S, Wang J, Hu X, Zhou RR, Fu Y, Tang D, et al.  Crosstalk between hepatitis B virus X and high-mobility group box 1 facilitates autophagy in hepatocytes. Mol Oncol. 2018;12(3):322–338. doi: 10.1002/1878-0261.12165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12165</ArticleId>
            <ArticleId IdType="pmc">PMC5830655</ArticleId>
            <ArticleId IdType="pubmed">29316268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Li N, Huang ZB, Fu S, Yu SM, Fu YM, et al.  HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma. Oncogene. 2019;38(40):6696–6710. doi: 10.1038/s41388-019-0907-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-019-0907-2</ArticleId>
            <ArticleId IdType="pubmed">31391550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fessart D, Marza E, Taouji S, Delom F, Chevet E. P97/CDC-48: proteostasis control in tumor cell biology. Cancer Lett. 2013;337(1):26–34. doi: 10.1016/j.canlet.2013.05.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2013.05.030</ArticleId>
            <ArticleId IdType="pubmed">23726843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol. 2012;14(2):117–123. doi: 10.1038/ncb2407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2407</ArticleId>
            <ArticleId IdType="pubmed">22298039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Hei Y, Shu Q, Dong J, Gao Y, Fu H, et al.  VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS ONE. 2012;7(4):e35800. doi: 10.1371/journal.pone.0035800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0035800</ArticleId>
            <ArticleId IdType="pmc">PMC3335000</ArticleId>
            <ArticleId IdType="pubmed">22536440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Monden M, Yamamoto S, et al.  Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol. 2004;11(7):697–704. doi: 10.1245/ASO.2004.10.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/ASO.2004.10.018</ArticleId>
            <ArticleId IdType="pubmed">15231524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, et al.  Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. J Clin Oncol. 2003;21(13):2537–2544. doi: 10.1200/JCO.2003.12.102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2003.12.102</ArticleId>
            <ArticleId IdType="pubmed">12829673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto S, Tomita Y, Hoshida Y, Toyosawa S, Inohara H, Kishino M, et al.  Expression level of valosin-containing protein (VCP) as a prognostic marker for gingival squamous cell carcinoma. Ann Oncol. 2004;15(9):1432–1438. doi: 10.1093/annonc/mdh354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdh354</ArticleId>
            <ArticleId IdType="pubmed">15319251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asai T, Tomita Y, Nakatsuka S, Hoshida Y, Myoui A, Yoshikawa H, et al.  VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res. 2002;93(3):296–304. doi: 10.1111/j.1349-7006.2002.tb02172.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2002.tb02172.x</ArticleId>
            <ArticleId IdType="pmc">PMC5926968</ArticleId>
            <ArticleId IdType="pubmed">11927012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Tu Y, He LI, Ji C, Cheng BO. High mobility group box 1 regulates tumor metastasis in cutaneous squamous cell carcinoma via the PI3K/AKT and MAPK signaling pathways. Oncol Lett. 2016;11(1):59–62. doi: 10.3892/ol.2015.3843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2015.3843</ArticleId>
            <ArticleId IdType="pmc">PMC4727160</ArticleId>
            <ArticleId IdType="pubmed">26870167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Xiang L, Li H, Chen P, Feng Y, Zhang J, et al.  The role of HMGB1 signaling pathway in the development and progression of hepatocellular carcinoma: a review. Int J Mol Sci. 2015;16(9):22527–22540. doi: 10.3390/ijms160922527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms160922527</ArticleId>
            <ArticleId IdType="pmc">PMC4613322</ArticleId>
            <ArticleId IdType="pubmed">26393575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen R, Hou W, Zhang Q, Kang R, Fan XG, Tang D. Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med. 2013;19:357–366. doi: 10.2119/molmed.2013.00099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2119/molmed.2013.00099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang QB, Jia QA, Wang H, Hu CX, Sun D, Jiang RD, et al.  High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis. BMC Cancer. 2016;16(1):880. doi: 10.1186/s12885-016-2883-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-016-2883-z</ArticleId>
            <ArticleId IdType="pmc">PMC5106788</ArticleId>
            <ArticleId IdType="pubmed">27836008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen RC, Yi PP, Zhou RR, Xiao MF, Huang ZB, Tang DL, et al.  The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem. 2014;390(1–2):271–280. doi: 10.1007/s11010-014-1978-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11010-014-1978-6</ArticleId>
            <ArticleId IdType="pmc">PMC3972434</ArticleId>
            <ArticleId IdType="pubmed">24510323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Handke NA, Rupp ABA, Trimpop N, von Pawel J, Holdenrieder S. Soluble high mobility group box 1 (HMGB1) is a promising biomarker for prediction of therapy response and prognosis in advanced lung cancer patients. Diagnostics. 2021 doi: 10.3390/diagnostics11020356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/diagnostics11020356</ArticleId>
            <ArticleId IdType="pmc">PMC8774963</ArticleId>
            <ArticleId IdType="pubmed">35054245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu W, Li J, Zhang Y, Zhu Z, Liu H, Lin Y, et al.  Inhibition of HMGB1 suppresses hepatocellular carcinoma progression via HIPK2-mediated autophagic degradation of ZEB1. Front Oncol. 2021;11:599124. doi: 10.3389/fonc.2021.599124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2021.599124</ArticleId>
            <ArticleId IdType="pmc">PMC7969871</ArticleId>
            <ArticleId IdType="pubmed">33747917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng H, Jiang W, Song Z, Li T, Li Y, Zhang L, et al.  Circular RNA circLPAR3 facilitates esophageal squamous cell carcinoma progression through upregulating HMGB1 via sponging miR-375/miR-433. Onco Targets Ther. 2020;13:7759–7771. doi: 10.2147/OTT.S244699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S244699</ArticleId>
            <ArticleId IdType="pmc">PMC7414984</ArticleId>
            <ArticleId IdType="pubmed">32801782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng X, Wu C, Yang M, Liu Q, Li H, Liu J, et al.  Role of PI3K/Akt signal pathway on proliferation of mesangial cell induced by HMGB1. Tissue Cell. 2016;48(2):121–125. doi: 10.1016/j.tice.2015.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tice.2015.12.007</ArticleId>
            <ArticleId IdType="pubmed">26822343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi: 10.1073/pnas.0506580102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId>
            <ArticleId IdType="pmc">PMC1239896</ArticleId>
            <ArticleId IdType="pubmed">16199517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang H, Zhu J, Du W, Liu S, Zeng Y, Ding Z, et al.  CPNE1 is a target of miR-335-5p and plays an important role in the pathogenesis of non-small cell lung cancer. J Exp Clin Cancer Res. 2018;37(1):131. doi: 10.1186/s13046-018-0811-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-018-0811-6</ArticleId>
            <ArticleId IdType="pmc">PMC6029376</ArticleId>
            <ArticleId IdType="pubmed">29970127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Fu Y, Hu X, Sun L, Tang D, Li N, et al.  The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1. Cell Death Dis. 2019;10(6):405. doi: 10.1038/s41419-019-1650-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-1650-x</ArticleId>
            <ArticleId IdType="pmc">PMC6538608</ArticleId>
            <ArticleId IdType="pubmed">31138777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X, Yu Y, Zong K, Lv P, Gu Y. Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic cancer promotes cancer proliferation by activating the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 2019;38(1):497. doi: 10.1186/s13046-019-1470-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1470-y</ArticleId>
            <ArticleId IdType="pmc">PMC6921559</ArticleId>
            <ArticleId IdType="pubmed">31852504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386. doi: 10.1002/ijc.29210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi: 10.1053/j.gastro.2015.12.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2015.12.041</ArticleId>
            <ArticleId IdType="pubmed">26795574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223–238. doi: 10.1016/j.cld.2015.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cld.2015.01.001</ArticleId>
            <ArticleId IdType="pmc">PMC4712629</ArticleId>
            <ArticleId IdType="pubmed">25921660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer MF, Seuthe IM, Drebber U, Siefer O, Kreppel M, Klein MO, et al.  Valosin-containing protein (VCP/p97)-expression correlates with prognosis of HPV- negative oropharyngeal squamous cell carcinoma (OSCC) PLoS ONE. 2014;9(12):e114170. doi: 10.1371/journal.pone.0114170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0114170</ArticleId>
            <ArticleId IdType="pmc">PMC4252085</ArticleId>
            <ArticleId IdType="pubmed">25463965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto S, Tomita Y, Hoshida Y, Sakon M, Kameyama M, Imaoka S, et al.  Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res. 2004;10(2):651–657. doi: 10.1158/1078-0432.CCR-1576-03.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-1576-03</ArticleId>
            <ArticleId IdType="pubmed">14760088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Kidogami S, Miyata H, et al.  Expression level of valosin-containing protein (p97) is associated with prognosis of esophageal carcinoma. Clin Cancer Res. 2004;10(16):5558–5565. doi: 10.1158/1078-0432.CCR-0723-03.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-0723-03</ArticleId>
            <ArticleId IdType="pubmed">15328197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valle CW, Min T, Bodas M, Mazur S, Begum S, Tang D, et al.  Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS ONE. 2011;6(12):e29073. doi: 10.1371/journal.pone.0029073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0029073</ArticleId>
            <ArticleId IdType="pmc">PMC3245239</ArticleId>
            <ArticleId IdType="pubmed">22216170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamanaka K, Sasagawa Y, Ogura T. Recent advances in p97/VCP/Cdc48 cellular functions. Biochim Biophys Acta. 2012;1823(1):130–137. doi: 10.1016/j.bbamcr.2011.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2011.07.001</ArticleId>
            <ArticleId IdType="pubmed">21781992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao BY, Lin WS, She FF, Chen WN, Lin X. Hepatitis B virus X protein enhances activation of nuclear factor kappaB through interaction with valosin-containing protein. Arch Virol. 2011;156(11):2015–2021. doi: 10.1007/s00705-011-1099-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00705-011-1099-4</ArticleId>
            <ArticleId IdType="pubmed">21918864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue J, Suarez JS, Minaai M, Li S, Gaudino G, Pass HI, et al.  HMGB1 as a therapeutic target in disease. J Cell Physiol. 2021;236(5):3406–3419. doi: 10.1002/jcp.30125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.30125</ArticleId>
            <ArticleId IdType="pmc">PMC8104204</ArticleId>
            <ArticleId IdType="pubmed">33107103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou RR, Kuang XY, Huang Y, Li N, Zou MX, Tang DL, et al.  Potential role of High mobility group box 1 in hepatocellular carcinoma. Cell Adh Migr. 2014;8(5):493–498. doi: 10.4161/19336918.2014.969139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/19336918.2014.969139</ArticleId>
            <ArticleId IdType="pmc">PMC4594547</ArticleId>
            <ArticleId IdType="pubmed">25482616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang WJ, Yang HW, Liu HN, Qian W, Chen XL. HMGB1 upregulates NF-kB by inhibiting IKB-α and associates with diabetic retinopathy. Life Sci. 2020;241:117146. doi: 10.1016/j.lfs.2019.117146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2019.117146</ArticleId>
            <ArticleId IdType="pubmed">31816325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Chen L, Yang J, Ding J, Rong H, Dong W, et al.  High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K/Akt pathway activation. Mol Biol Rep. 2012;39(3):3361–3367. doi: 10.1007/s11033-011-1106-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11033-011-1106-6</ArticleId>
            <ArticleId IdType="pubmed">21698364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heidelberger JB, Voigt A, Borisova ME, Petrosino G, Ruf S, Wagner SA, et al.  Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. EMBO Rep. 2018 doi: 10.15252/embr.201744754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embr.201744754</ArticleId>
            <ArticleId IdType="pmc">PMC5891417</ArticleId>
            <ArticleId IdType="pubmed">29467282</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
